+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Cognitive Disorders Drugs"

Cognitive Disorders Global Clinical Trials Review, H2, 2019 - Product Thumbnail Image

Cognitive Disorders Global Clinical Trials Review, H2, 2019

  • Clinical Trials
  • December 2019
  • 1870 Pages
  • Global
From
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Pipeline Review, H2 2018 - Product Thumbnail Image

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Pipeline Review, H2 2018

  • Drug Pipelines
  • August 2018
  • 78 Pages
  • Global
From
  • 2 Results (Page 1 of 1)
Loading Indicator

The Cognitive Disorders Drugs market is a subset of the Central Nervous System Drugs market, which includes drugs used to treat neurological and psychiatric disorders. Cognitive Disorders Drugs are used to treat conditions such as Alzheimer's disease, dementia, and other cognitive impairments. These drugs are designed to improve cognitive function, memory, and concentration. They may also be used to treat anxiety, depression, and other mental health issues. Common Cognitive Disorders Drugs include cholinesterase inhibitors, memantine, and antipsychotics. Companies in the Cognitive Disorders Drugs market include AbbVie, AstraZeneca, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more